Sarepta Therapeutics annual operating expenses
2012
2013
2014
2015
2016
2017
2018
2019
2022
2023
2024
2025
Sarepta Therapeutics Operating Expenses Growth & History (SRPT)
Sarepta Therapeutics's operating expenses was $2.54B for fiscal 2025.
View full Sarepta Therapeutics company overviewSarepta Therapeutics annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.54B | $1.17B | +86.00% |
| 2024 | 2024-12-31 | $1.36B | $4.0M | +0.29% |
| 2023 | 2023-12-31 | $1.36B | $31.6M | +2.38% |
| 2022 | 2022-12-31 | $1.33B | — | — |
| 2019 | 2019-12-31 | $1.09B | $441.7M | +68.52% |
| 2018 | 2018-12-31 | $644.7M | $318.4M | +97.61% |
| 2017 | 2017-12-31 | $326.2M | $54.1M | +19.87% |
| 2016 | 2016-12-31 | $272.2M | $50.7M | +22.90% |
| 2015 | 2015-12-31 | $221.4M | $77.9M | +54.26% |
| 2014 | 2014-12-31 | $143.5M | $39.0M | +37.36% |
| 2013 | 2013-12-31 | $104.5M | $37.5M | +55.90% |
| 2012 | 2012-12-31 | $67.0M | — | — |
Sarepta Therapeutics quarterly operating expenses
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $199.6M | −$45.4M | −18.54% |
| Q1 2026 | 2026-03-31 | $263.6M | −$510.7M | −65.96% |
| Q4 2025 | 2025-12-31 | $1.20B | $852.4M | +247.67% |
| Q3 2025 | 2025-09-30 | $322.7M | $6.8M | +2.14% |
| Q2 2025 | 2025-06-30 | $245.0M | −$71.7M | −22.64% |
| Q1 2025 | 2025-03-31 | $774.3M | $500.3M | +182.59% |
| Q4 2024 | 2024-12-31 | $344.2M | — | — |
| Q3 2024 | 2024-09-30 | $315.9M | — | — |
| Q2 2024 | 2024-06-30 | $316.7M | — | — |
| Q1 2024 | 2024-03-31 | $274.0M | — | — |
| Q4 2019 | 2019-12-31 | $330.3M | $106.6M | +47.62% |
| Q3 2019 | 2019-09-30 | $222.6M | $74.0M | +49.83% |
| Q2 2019 | 2019-06-30 | $370.0M | $193.1M | +109.11% |
| Q1 2019 | 2019-03-31 | $163.4M | $68.1M | +71.38% |
| Q4 2018 | 2018-12-31 | $223.8M | $143.4M | +178.25% |
| Q3 2018 | 2018-09-30 | $148.6M | $56.7M | +61.75% |
| Q2 2018 | 2018-06-30 | $177.0M | $78.6M | +79.92% |
| Q1 2018 | 2018-03-31 | $95.3M | $39.8M | +71.52% |
| Q4 2017 | 2017-12-31 | $80.4M | −$13.4M | −14.27% |
| Q3 2017 | 2017-09-30 | $91.9M | $35.3M | +62.49% |
| Q2 2017 | 2017-06-30 | $98.3M | $36.3M | +58.37% |
| Q1 2017 | 2017-03-31 | $55.6M | −$4.1M | −6.89% |
| Q4 2016 | 2016-12-31 | $93.8M | $28.1M | +42.78% |
| Q3 2016 | 2016-09-30 | $56.5M | $4.8M | +9.22% |
| Q2 2016 | 2016-06-30 | $62.1M | $20.0M | +47.48% |
| Q1 2016 | 2016-03-31 | $59.7M | −$2.2M | −3.49% |
| Q4 2015 | 2015-12-31 | $65.7M | $21.0M | +46.83% |
| Q3 2015 | 2015-09-30 | $51.8M | $17.0M | +49.03% |
| Q2 2015 | 2015-06-30 | $42.1M | $9.3M | +28.16% |
| Q1 2015 | 2015-03-31 | $61.9M | $30.7M | +98.22% |
| Q4 2014 | 2014-12-31 | $44.7M | $9.3M | +26.14% |
| Q3 2014 | 2014-09-30 | $34.7M | $5.6M | +19.36% |
| Q2 2014 | 2014-06-30 | $32.9M | $12.8M | +63.96% |
| Q1 2014 | 2014-03-31 | $31.2M | $11.3M | +56.92% |
| Q4 2013 | 2013-12-31 | $35.5M | — | — |
| Q3 2013 | 2013-09-30 | $29.1M | — | — |
| Q2 2013 | 2013-06-30 | $20.0M | — | — |
| Q1 2013 | 2013-03-31 | $19.9M | — | — |
Sarepta Therapeutics operating expenses trends
Between the periods ended 2012-12-31 and 2025-12-31, Sarepta Therapeutics's operating expenses increased from $67.0M to $2.54B, a change of $2.47B. The latest reported quarter, Q2 2026, shows $199.6M.
About the metric
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
Calculation and source
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sarepta Therapeutics source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...